Knowledge

Collections with the topic tag  Opioid

  • Pethidine/Meperidine

     

    Pethidine (Meperidine) is a phenylpiperidine synthetic opioid first synthesized in 1938. Although widely used in the 20th century, it has fallen out of favour over the past decade due to abuse potential, limited advantages over other opioids and the existence of toxic metabolites.

    A. Physiochemistry

    • pKa - 8.5 (9% nonionised @ 7.4)
    • Octanol water coefficient - 39 (so 40x lipid solubility of morphine)
    • phenylpiperidine opioid

    B. Pharmacokinetics

    1. Dose - 25-100 mg (10% morphine potency). Limit 1000 mg 1st day, then 600 mg/day there after.
    2. Absorption - IV, IM, epidural, po (55% biov)
    3. Distribution - Vdss 4.5 L/kg. Crosses placenta - foetal 80% of maternal.
    4. Protein binding - 60%
    5. Onset 10 min ; Offset 2-3 h
    6. Metabolism - ß½ 3 h; N-demethylation to norpethidine and then hydrolysis to norpethidinic acid; also direct hydrolysis to pethidinic acid. Renal elimination.
      • Norpethidine - ß½ 15 h; 50% analgesic properties, 2x convulsant effects.
    7. Clearance - 20 mL/kg/min (same as morph & fentanyl)

    C. Pharmacodynamics

    1. Mech - mu and kappa agonist, causing potent spinal and supraspinal analgesia.
    2. CNS - more euphoria, less N/V than morphine. No miosis, but may cause mydriasis (pupil dilation -atropine-like kappa action). No EEG changes like morphine. ⇡ latency & amplitude of SSEPs.
      • NB: has LA action, so can be used as sole agent for neuroaxial block.
      • anti-shivering effect (kappa)
    3. CVS - ⇣ MAP (> than morphine) due to histamine release & alpha adrenergic blockade (vasodilation). Inc HR (atropine like effect). Large doses depress myocardial contractility. May cause hypertensive crisis in those on MAOIs.
      • vasodilation
      • tachycardia
      • depress myocardial contractility
    4. Resp - potent resp depressant - greater effect on TV than RR. Histamine release. Chest wall rigidity.
    reference

    expand collection

  • Sufentanil

     

    Sulfentanil is a potent, short-acting synthetic opioid used in anesthesia and critical care. First synthesized by Janssen Pharmaceutica in 1974. It is the most potent opioid licensed for use in humans.

    • OWC 1800
    • pKa 8.0
    • Potency 5-10x fentanyl, 500x morphine.
    • Vd 3 L/kg
    • Protein binding 93%
    • Clearance 12 mL/kg/min
    • tß½ 3 hours
    • CSHT(8h) 30 min (alfentanil ~60 m)
    • mu agonist, also stimulates serotonin release and at high dose has local anaeshetic effect.
    • Structurally different from fentanyl, with a methoxymethyl group on the piperidine ring (increases potency and reduces duration of action) and thiophene instead of phenyl ring.
    reference

    expand collection

  • Morphine

     

    Morphine is one of the most commonly used opioids worldwide. First isolated in 1803 and commercially marketed by Merck in 1827.

    A. Physiochemistry

    • Natural phenathrene opioid - plant, animal and even human synthesis identified.
      • Synthesized by mammalian cells from dopamine, although exact role unclear.
    • pKa - 7.9 (20% nonionised @ 7.4)
    • Octanol water coefficient - 1.4 (relatively low lipid solubility compared with other opioids)
    • 3 rings attached to piperidine ring with a tertiary amine.

    B. Pharmacokinetics

    1. Dose - 50 mcg/kg IV
      • analgesia @ [plasma] 0.05 mcg/mL
      • epidural: 10-20 mcg/mL
      • PCA adult: 50 mg in 50 mL; 1 mL (1 mg) bolus 5 min lockout, commonly used.
      • PCA paeds: 1 mg/kg in 50 mL; 1 mL (20 mcg/kg) bolus; background 0.5-1 mL/h (10-20 mcg/kg/h).
    2. Absorption - IV, IM, s/c, po (3x dose as HER 0.69)
    3. Distribution - Vdcc 0.3, Vdss 3.5 L/kg
    4. Protein binding - 30% (albumin)
    5. Onset: peak onset at 20 min when given parenteral, 60 min orally; Offset 4 h
    6. Metabolism - t½α 10-20 min, t½ß 2-4 h
      • 75% metabolised by conjugation → 90% morphine-3-glucuronide (no activity)
      • 10% morphine-6-gluc (13x potency of morphine). MAOIs inhibit glucuronidation.
    7. Clearance - 15 mL/kg/min

    C. Pharmacodynamics

    1. Mech - mu, kappa, delta agonist. (GI linked). Effective against visceral, skeletal & joint pain.
    2. CNS - little CNS penetration (cf. heroin, which readily crosses BBB), although alkalisation (⇣pCO2) ⇡ non-ionised fraction, and ⇡pCO2 ⇡CBF. Both ⇡ cerebral morphine concentration.
      • 'Ceiling effect' on EEG reaching high voltage, slow frequency (delta 2-4 Hz) waves.
      • ⇣ CMRO2 & ⇣ ICP.
      • ⇡ cortical stimulation of Edinger-Westphal nucleus → miosis.
    3. CVS - ⇣ SNS & ⇡ PNS tone. Bradycardia, venodilation, histamine release (causes ⇣ MAP). Orthostatic hypotension due to depression of SNS responses. Direct depressant effect on SA node, slowing conduction (⇡ VF risk).
      • Administration with N2O results in CVS depression.
    4. Resp - Respiratory depression & response to CO2 & hypoxia (shift pCO2/VA curve to right).
      • Bronchoconstriction due to histamine release (similar with pethidine). Depresses airway reflexes & ciliary reflexes.
    5. Renal - diuresis (kappa receptors → ADH release)
    6. GIT - Nausea & vomiting due to stimulation of CTZ (30-40% of subjets); ileus; constipation; sphincter of Oddi spasm.
    7. Pruritus
    reference

    expand and show 1 more article

  • Tapentadol

     

    Tapentadol (Paliex™, Nucynta™) is a synthetic opioid agonist and noradrenaline-reuptake inhibitor. Similar to and based upon tramadol, although with much weaker inhibition (by design) of serotonin reuptake.

    A. Physiochemistry

    • Synthetic analgesic of 'amino-cyclo-hexanol' group.
    • Unlike tramadol, prepared as only the (R,R) stereoisomer (weakest opioid activity).
    • Oral: 50, 75 & 100 mg immediate release, and 50,100,150 & 200 mg extended release preparations.
    • No parenteral preparation is approved for use.

    B. Pharmacokinetics

    1. Dose: 50-200 mg bd/qid for immediate release preparations, 50-200mg bd for extended release.
      • approximately double potency of tramadol, similar to oxycodone and between tramadol and morphine.
    2. Absorption - po (only 32% biov)
      • increasing doses have a non-linear effect on increasing peak plasma concentration, thus higher doses result in disproportionately higher Cmax.
    3. Distribution - ~8 L/kg (higher than tramadol).
    4. Protein binding - 20% (low!)
    5. Onset 30 min; Offset 4-6 h
    6. Metabolism - t½ 4h
      • hepatic conjugation with glucuronic acid → glucuronides is main pathway (tapentadol-O-glucuronide); p450 metabolism to N-desmethyl tapentadol and hydroxyl tapentadol.
      • No known active metabolites
      • 99% excreted in urine, 1% in faecies.
    7. Clearance - 22 mL/kg/min

    C. Pharmacodynamics

    1. Mech - weak mu agonists (30% of action / 18x less affinity than morphine) ; inhibits NAd reuptake (through indirect activation of post-synaptic alpha-2 adrenoreceptors), activating descending NAd (70%) modulating pain pathways.
    2. CNS - analgesia, good for neuropathic pain, low(er) incidence of tolerance & dependence, lowers seizure threshold, dizziness, sweating, ⇡ ICP.
    3. CVS - few CVS effects. Some tachycardia and flushing.
    4. Resp - little respiratory depression.
    5. Renal - possible caution in renal failure, although no active metabolites even if 99% renal excreted.
    6. GIT - Nausea & vomiting (less than tramadol), minimal constipation, more biliary spasm than tramadol.
    7. SEs - interacts with MAOI (adrenergic storm), SSRIs (serotonin syndrome).
    • Although thought to have less abuse potential than other common opioids, it is still classed as a Schedule 2 drug in the US, Schedule 1 in Canada, Class A controlled drug in the UK and S8 in Australia.
    • Safety of tapentadol in pregnant, lactating women, and pediatric patients is not yet established. 
    reference

    expand and show 1 more article

  • Tramadol

     

    Tramadol is a synthetic opioid agonist and neurotransmitter-modulating analgesic.

    A. Physiochemistry

    • Synthetic analgesic of 'amino-cyclo-hexanol' group.
    • Racemic mixture of two enantiomers + and -:
      • (-) Inhibits NAd reuptake
      • (+) Enhances 5HT release, inhibits 5HT reuptake, weak mu (& less kapaa/delta) agonist.
    • Oral (50 mg capsules, 100 mg tablets) & parenteral (100 mg/2mL) preparations.
    • pKa 9.4

    B. Pharmacokinetics

    1. Dose - 5-10x less potent than morphine: 50-100 mg q6h, max 400-600 mg/day.
      • 2-3 mg/kg loading, then 1-2 mg/kg q6h.
      • PCA IV tramadol: 20 mg/mL then step down to oral (Prof Schug, Perth: 25-50 mg q1h PCA, using up to 1500 mg/24h).
      • analgesic efficacy and potency comparable to pethidine
      • Caudal: 2 mg/kg
    2. Absorption - IV, IM, po (80% biov)
    3. Distribution - 3 L/kg (80% crosses placenta).
    4. Protein binding - 20%
    5. Onset 30 min; Offset 6 h
      • peak [plasma] after po: 2h
    6. Metabolism - t½ 6h (12h in renal impairment);
      • 85% p450 (CYP-2D6 - also converts codeine → morphine & metabolises ondansetron!)
      • Demethylation to 'O-demethyl-tramadol' (M1) t½ 9h - has some activity as it has 6x greater mu affinity than tramadol. Some consider tramadol a prodrug because of this.
      • 90% excreted in urine, 10% in faecies.
      • metabolism inhibited by quinidine
    7. Clearance - 9 mL/kg/min

    C. Pharmacodynamics

    1. Mech - weak mu agonists (30% of action) (very weak kappa & delta); inhibits NAd reuptake (through indirect activation of post-synaptic alpha-2 adrenoreceptors) and stimulates 5HT release, so activates desc NAd and 5HT pathways (70%), modulating pain pathways.
      • Naloxone antagonises only 30% tramadol analgesic effect. Ondansetron antagonises a further 30% of tramadol analgesic effect.
    2. CNS - analgesia, good for neuropathic pain, low(er) incidence of tolerance & dependence, lowers seizure threshold, dizziness, sweating.
      • stops shivering?
    3. CVS - few CVS effects. Some tachycardia and flushing.
    4. Resp - little respiratory depression.
    5. Renal - caution in renal failure.
    6. GIT - Nausea & vomiting (30-40%, like morphine), minimal constipation, minimal biliary spasm.
    7. SEs - interacts with MAOI, SSRIs.
    • Quinidine may decrease efficacy of tramadol by inhibiting CYP-2D6, thus decreasing production of M1. Codeine my compete for the same enzyme with a similar result.
    • Carbamazepine induces CYP-2D6 decreasing effect by increasing metabolism.
    reference

    expand and show 4 more articles